Loading...

OncoCyte Corporation

0KCC.L•LSE
Healthcare
Medical - Pharmaceuticals
£2.66
£-0.74(-21.80%)

OncoCyte Corporation (0KCC.L) Stock Overview

Explore OncoCyte Corporation’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 66.2/100

Key Financials

Market Cap78.4M
P/E Ratio-1.33
EPS (TTM)$-0.77
ROE-7.67%
Fundamental Analysis

AI Price Forecasts

1 Week$3.22
1 Month$3.52
3 Months$3.45
1 Year Target$6.10

0KCC.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of OncoCyte Corporation (0KCC.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.23, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $6.10.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.33 and a market capitalization of 78.4M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

48.23RSI (14)
0.05MACD
23.56ADX
Revenue Growth
25.15%
↑ 25.15%
Profit Growth
£-2.27
↓ 118.36%
EPS Growth
£-2.27
↓ 24.27%
Operating Margin
-1524.15%
↓ 142.84%
ROE
-766.91%
↓ 118.36%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 0KCC.LAnalyst Recommendations details for 0KCC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

CEO

Joshua Riggs

Employees

46

Headquarters

15 Cushing, Irvine, CA

Founded

2018

Frequently Asked Questions

;